After 18 months of follow-up of patients in the Prostate Cancer Prevention Trial (PCPT), Ian M. Thompson, Jr. MD, and colleagues found that finasteride decreased the risk of prostate cancer (PCa) by about a one third, but it had no effect on overall survival or survival after the diagnosis of PCa, according to a report in the New England Journal of Medicine (2013;369:603-610). 

In an editorial accompanying the report, Michael LeFevre, MD, wrote that the safest conclusion one can draw about the use of finasteride for PCa prevention “is that it has no short- or long-term effect on all-cause mortality, so we cannot recommend its use to prolong life.” 

Renal & Urology News invites urologists to answer the following online poll question.

Continue Reading